BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
HDFC Securities Recommends 'Buy' On Laurus Labs
According to HDFC Securities, Laurus Labs is in the process of transition from an API player to an integrated oral solid formulation player. The recent approval for its manufacturing units by USFDA and patent expiry of key ARV drugs will open doors for entry into the lucrative US and EU generics market, the brokerage adds.